Preview Mode Links will not work in preview mode

Clinical Literature Summaries presented by InpharmD™ (S3)

Sep 28, 2021

A randomized, double-blind, parallel-group, placebo-controlled, event-driven trial conducted to evaluate the effects of SGLT2 inhibition with empagliflozin on major heart failure outcomes in patients with heart failure and a preserved ejection fraction.